Novartis paid Takeda $3.4 billion for its FDA-approved dry eye drug Xiidra during the Japanese ... FDA approval of a phase 3 trial for eye drops containing tivanisiran, in dry eye disease associat ...

Some patients may respond better to one medication than the other based on the drug's reasons for use ... and effectiveness of using both eye drops together. Xiidra and Restasis can be used ...

Shire’s CEO Flemming Ornskov has hailed the launch of ophthalmology drug Xiidra ... call about Xiidra, a blockbuster hopeful that Shire stuck with despite a rejection in dry eye disease by ...

Restasis (cyclosporine) is a brand-name drug that’s prescribed for chronic dry eye in adults and certain children. Restasis comes as an eye drop solution. The typical dosage is one drop per ...

Bausch + Lomb is acquiring Johnson & Johnson’s Blink line of eye drops. The deal comes as J ... Dry eye disease drug Xiidra is the centerpiece of the Bausch + Lomb acquisition.